AP2502A - 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses - Google Patents

3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses

Info

Publication number
AP2502A
AP2502A AP2009004931A AP2009004931A AP2502A AP 2502 A AP2502 A AP 2502A AP 2009004931 A AP2009004931 A AP 2009004931A AP 2009004931 A AP2009004931 A AP 2009004931A AP 2502 A AP2502 A AP 2502A
Authority
AP
ARIPO
Prior art keywords
forenhancing
substituted
synaptic responses
glutamatergic synaptic
benzotriazinone
Prior art date
Application number
AP2009004931A
Other languages
English (en)
Other versions
AP2009004931A0 (en
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Servier Lab
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Cortex Pharma Inc filed Critical Servier Lab
Publication of AP2009004931A0 publication Critical patent/AP2009004931A0/xx
Application granted granted Critical
Publication of AP2502A publication Critical patent/AP2502A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2009004931A 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses AP2502A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Publications (2)

Publication Number Publication Date
AP2009004931A0 AP2009004931A0 (en) 2009-08-31
AP2502A true AP2502A (en) 2012-10-23

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009004931A AP2502A (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses

Country Status (38)

Country Link
US (1) US8173644B2 (xx)
EP (1) EP2144506B1 (xx)
JP (1) JP5139446B2 (xx)
CN (1) CN101616592B (xx)
AP (1) AP2502A (xx)
AR (1) AR064740A1 (xx)
AT (1) ATE527269T1 (xx)
AU (1) AU2007342365B2 (xx)
BR (1) BRPI0720749A2 (xx)
CA (1) CA2674460C (xx)
CR (1) CR10906A (xx)
CU (1) CU23804B7 (xx)
CY (1) CY1112493T1 (xx)
DK (1) DK2144506T3 (xx)
EA (1) EA017437B1 (xx)
EC (1) ECSP099499A (xx)
ES (1) ES2374995T3 (xx)
GE (1) GEP20125438B (xx)
GT (1) GT200900189A (xx)
HK (1) HK1140105A1 (xx)
HN (1) HN2009001268A (xx)
HR (1) HRP20110970T1 (xx)
IL (1) IL199651A (xx)
MA (1) MA31160B1 (xx)
ME (1) ME00819B (xx)
MX (1) MX2009007242A (xx)
MY (1) MY154877A (xx)
NI (1) NI200900131A (xx)
NZ (1) NZ578293A (xx)
PL (1) PL2144506T3 (xx)
PT (1) PT2144506E (xx)
RS (1) RS52108B (xx)
SG (1) SG163545A1 (xx)
SI (1) SI2144506T1 (xx)
SV (1) SV2009003322A (xx)
TN (1) TN2009000277A1 (xx)
WO (1) WO2008085506A1 (xx)
ZA (1) ZA200904826B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090098999A (ko) * 2007-01-03 2009-09-18 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 3-치환된-[1,2,3]벤조트리아지논 화합물
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
CA2695742C (en) 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
WO2013075624A1 (zh) 2011-11-22 2013-05-30 北京哈三联科技股份有限公司 甘氨酸重摄取抑制剂及其应用
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
CA2988572A1 (en) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
PT1156043E (pt) 1992-07-24 2004-03-31 Univ California Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
ES2128629T3 (es) * 1994-10-31 1999-05-16 Merck Patent Gmbh Derivados de bencilpiperidina con afinidad elevada a puntos de enlace de receptores de aminoacidos.
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
ZA991301B (en) 1998-02-18 1999-09-13 Neurosearch As Glutamate receptor modulators.
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
EP1448537A4 (en) * 2001-11-26 2005-05-04 Cortex Pharma Inc CARBONYLBENZOXAZINIC COMPOUNDS ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
NZ540468A (en) * 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
KR20090098999A (ko) 2007-01-03 2009-09-18 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 3-치환된-[1,2,3]벤조트리아지논 화합물
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
CA2695742C (en) 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
MX2010002890A (es) * 2007-09-20 2010-07-02 Cortex Pharma Inc 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Murray et al., LY503430, a novel AMPA receptor potentiator with functional , neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2003, vol. 306, pp. 752-762. *

Also Published As

Publication number Publication date
PL2144506T3 (pl) 2012-04-30
MY154877A (en) 2015-08-14
EP2144506A1 (en) 2010-01-20
GT200900189A (es) 2011-08-02
PT2144506E (pt) 2011-12-21
US8173644B2 (en) 2012-05-08
CR10906A (es) 2009-10-23
WO2008085506A1 (en) 2008-07-17
ATE527269T1 (de) 2011-10-15
SG163545A1 (en) 2010-08-30
TN2009000277A1 (en) 2010-10-18
AU2007342365A1 (en) 2008-07-17
CN101616592A (zh) 2009-12-30
HK1140105A1 (en) 2010-10-08
DK2144506T3 (da) 2012-03-05
CU20090117A7 (es) 2011-10-05
AU2007342365B2 (en) 2012-11-15
CY1112493T1 (el) 2015-12-09
AP2009004931A0 (en) 2009-08-31
CN101616592B (zh) 2013-06-05
SI2144506T1 (sl) 2012-01-31
ME00819B (me) 2012-03-20
EA200900925A1 (ru) 2009-12-30
JP2010514838A (ja) 2010-05-06
ECSP099499A (es) 2009-10-30
MA31160B1 (fr) 2010-02-01
MX2009007242A (es) 2009-09-02
NZ578293A (en) 2012-01-12
HRP20110970T1 (hr) 2012-01-31
IL199651A (en) 2015-08-31
AR064740A1 (es) 2009-04-22
ZA200904826B (en) 2010-09-29
US20100137295A1 (en) 2010-06-03
CA2674460A1 (en) 2008-07-17
HN2009001268A (es) 2011-12-27
CA2674460C (en) 2014-07-15
NI200900131A (es) 2010-03-11
EP2144506B1 (en) 2011-10-05
SV2009003322A (es) 2010-02-05
IL199651A0 (en) 2010-04-15
EA017437B1 (ru) 2012-12-28
JP5139446B2 (ja) 2013-02-06
BRPI0720749A2 (pt) 2014-01-14
ES2374995T3 (es) 2012-02-23
GEP20125438B (en) 2012-03-26
EP2144506A4 (en) 2010-05-05
RS52108B (en) 2012-08-31
CU23804B7 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
AP2502A (en) 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses
EP2136810A4 (en) NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS
IL201973A0 (en) 3,3-spiroindolinone derivatives
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
IL225694A0 (en) Compounds 6,5- dihydro-h1-pyridine-2-one
ZA200905065B (en) 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
EP2202231A4 (en) 2,3-DIHYDROIMINOISOINDOLE DERIVATIVE
IL201444A0 (en) New 4, 8 - diphenyl - polyazanaphthalene derivatives
HK1161684A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds 56- -1h--2-
HK1151801A1 (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid
BRPI0818848A2 (pt) Compostos de 2,3-di-idro-benzofurano
IL194972A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-
AU2007100045A4 (en) Kuvva 2
AU2007100060A4 (en) Kuvva 1
AU2007901207A0 (en) Animal contianment arrangement
IL211702A0 (en) Short synthetic pathway for 1,6:2,3-dianhydro-beta-d-mannopyranose
GB0702708D0 (en) IP.Access 2
GB0702705D0 (en) IP.Access 1
AU2007904007A0 (en) The fish hooka
AU2007900162A0 (en) Biovations 440
AU2007900161A0 (en) Biovations 770